101
Participants
Start Date
June 3, 2020
Primary Completion Date
August 21, 2025
Study Completion Date
August 21, 2025
ABBV-CLS-579
Oral Capsule
PD-1 inhibitor
Intravenous (IV) infusion
VEGFR TKI
Oral Tablet
National Taiwan University Hospital, Taipei
UPMC Hillman Cancer Center, Pittsburgh
Hospital Universitario Fundacion Jimenez Diaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario HM Sanchinarro, Madrid
Carolina BioOncology Institute, Huntersville
Hospital Universitario Virgen de la Victoria, Málaga
Hopital Saint-Andre, Bordeaux
Fort Wayne Medical Oncology and Hematology, Fort Wayne
Highlands Oncology Group Springdale, Springdale
Institut Gustave Roussy, Villejuif
The Chaim Sheba Medical Center, Ramat Gan
Yale University, New Haven
National Cancer Center Hospital East, Kashiwa-Shi
Wakayama Medical University Hospital, Wakayama
National Cancer Center Hospital, Chuo-ku, Tokyo
Seoul National University Hospital, Seoul
Lead Sponsor
Collaborators (1)
Calico Life Sciences LLC
INDUSTRY
AbbVie
INDUSTRY